Cargando…

Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens

A recombinant modified vaccinia Ankara (MVA) virus expressing mature viral protein 2 (VP2) of the infectious bursal disease virus (IBDV) was constructed to develop MVA-based vaccines for poultry. We demonstrated that this recombinant virus was able to induce a specific immune response by observing t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanetti, Flavia Adriana, Zajac, María Paula Del Médico, Taboga, Oscar Alberto, Calamante, Gabriela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Veterinary Science 2012
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386346/ https://www.ncbi.nlm.nih.gov/pubmed/22705743 http://dx.doi.org/10.4142/jvs.2012.13.2.199

Ejemplares similares

Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens
por: Zanetti, Flavia Adriana, et al.
Publicado: (2014)

Expression of immunogenic VP2 protein of infectious bursal disease virus in Arabidopsis thaliana
por: Wu, H., et al.
Publicado: (2004)

Assessing the antigenicity of different VP3 regions of infectious bursal disease virus in chickens from South Brazil
por: Palka, Ana Paula Gori, et al.
Publicado: (2021)

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
por: Calvo-Pinilla, Eva, et al.
Publicado: (2018)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Partial VP1 sequencing of Brazilian infectious bursal disease virus strains
por: Fernandes, Maria Judite Bittencourt, et al.
Publicado: (2012)

Efficacy of Fowlpox Virus Vector Vaccine Expressing VP2 and Chicken Interleukin-18 in the Protection against Infectious Bursal Disease Virus
por: Eldaghayes, Ibrahim, et al.
Publicado: (2023)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: López-Camacho, César, et al.
Publicado: (2019)

Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease
por: Sheppard, M., et al.
Publicado: (2014)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity
por: Alharbi, Naif Khalaf, et al.
Publicado: (2015)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Cyclophilin A Interacts with Viral VP4 and Inhibits the Replication of Infectious Bursal Disease Virus
por: Wang, Nian, et al.
Publicado: (2015)

Identification of Infectious Bursal Disease Virus with Atypical VP2 Amino Acid Profile in Latvia
por: Pikuła, Anna, et al.
Publicado: (2017)

Ghrelin attenuates infectious bursal disease virus–induced early inflammatory response and bursal injury in chicken
por: Yu, Yan, et al.
Publicado: (2020)

Infectious bursal disease virus in chickens: prevalence, impact, and management strategies
por: Dey, Sohini, et al.
Publicado: (2019)

The Infectious Bursal Disease Virus RNA-Binding VP3 Polypeptide Inhibits PKR-Mediated Apoptosis
por: Busnadiego, Idoia, et al.
Publicado: (2012)

Mutations of Residues 249 and 256 in VP2 Are Involved in the Replication and Virulence of Infectious Bursal Disease Virus
por: Qi, Xiaole, et al.
Publicado: (2013)

TRIM25 inhibits infectious bursal disease virus replication by targeting VP3 for ubiquitination and degradation
por: Wang, Suyan, et al.
Publicado: (2021)

An Ex Vivo Chicken Primary Bursal-cell Culture Model to Study Infectious Bursal Disease Virus Pathogenesis
por: Dulwich, Katherine L., et al.
Publicado: (2018)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus
por: Di Mario, Giuseppina, et al.
Publicado: (2017)

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
por: Magnusson, Sofia E., et al.
Publicado: (2018)

Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
por: Julander, Justin G., et al.
Publicado: (2018)

Isolation of Infectious Bursal Disease Virus Using Indigenous Chicken Embryos in Kenya
por: Mutinda, W. U., et al.
Publicado: (2015)

Comparison of the expression of cytokine genes in the bursal tissues of the chickens following challenge with infectious bursal disease viruses of varying virulence
por: Liu, Haiwen, et al.
Publicado: (2010)

Immunoreactivity and morphological changes of bursal follicles in chickens infected with vaccine or wild-type strains of the infectious bursal disease virus
por: AIHARA, Naoyuki, et al.
Publicado: (2015)

Glycoprotein Production by Bursal Secretory Dendritic Cells in Normal, Vaccinated, and Infectious Bursal Disease Virus (IBDV)-Infected Chickens
por: Felföldi, Balázs, et al.
Publicado: (2022)

Characterization of the RNA-binding activity of VP3, a major structural protein of Infectious bursal disease virus
por: Kochan, G., et al.
Publicado: (2003)

Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses
por: Holgado, María Pía, et al.
Publicado: (2016)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Infectious Bursal Disease Virus VP5 Polypeptide: A Phosphoinositide-Binding Protein Required for Efficient Cell-to-Cell Virus Dissemination
por: Méndez, Fernando, et al.
Publicado: (2015)

Study of coinfection with local strains of infectious bursal disease virus and infectious bronchitis virus in specific pathogen-free chickens
por: Jaton, Juan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mebis6vsafo7olja98rg35bd2o